Iruxol Mono (Collagenase Clostridium Histolyticum, Protease)

The collagenase enzyme selectively breaks down collagen and other extracellular matrix proteins that constitute dead or devitalized tissue. By hydrolyzing these structural proteins, the product softens and removes necrotic material without harming viable tissue, thereby facilitating a cleaner wound environment for regeneration.

The dosage and frequency of Iruxol Mono are determined by the prescribing clinician based on wound size, depth, and patient condition. The prescriber will specify the amount of product to apply, the interval between applications, and the total duration of therapy.

Safety data for Iruxol Mono in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Iruxol Mono, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Iruxol Mono’s collagenase enzyme offers selective enzymatic debridement, which can be gentler than mechanical or surgical methods and may preserve more healthy tissue compared with non‑specific proteolytic creams. It is often preferred when precise removal of necrotic tissue is required, whereas other agents may act more broadly or cause greater irritation.

Iruxol Mono should be stored below 25 °C in its original packaging, protected from moisture and direct light. Keep the container tightly closed when not in use and avoid exposing the product to extreme temperatures to maintain enzyme stability.

The product is applied topically to the cleaned wound surface using a sterile applicator or gloved finger, as directed by the prescriber. The recommended amount is spread evenly over the necrotic area, and the wound is then covered with an appropriate dressing if required.

Serious risks include severe allergic reactions such as anaphylaxis, extensive tissue damage from over‑debridement, secondary infections, and rare cases of necrotizing fasciitis. Patients should be monitored closely for signs of hypersensitivity, worsening ulceration, or systemic infection.

Iruxol Mono should not be used in individuals with a known hypersensitivity to collagenase, protease enzymes, or any excipients in the formulation. It is also contraindicated on healthy, non‑necrotic skin and should be avoided in patients where the risk of excessive tissue breakdown outweighs potential benefits.